Physician profile
Carson Tan Lo
NPI 1164483293
$12,505.29
in general payments reported to CMS, 2019-2025
33 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,176 · 2020: $2,158 · 2021: $2,396 · 2022: $2,235 · 2023: $2,200 · 2024: $1,239 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,540.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,429.32 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $1,838.42 | 2019-2024 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $1,124.19 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Insmed, INC. | $858.89 | 2019-2025 | Arikayce |
| Paratek Pharmaceuticals, INC. | $709.31 | 2019-2024 | Nuzyra |
| Abbvie INC. | $698.78 | 2021-2024 | |
| Janssen Biotech, INC. | $604.53 | 2019-2023 | Symtuza |
| Emd Serono, INC. | $559.26 | 2019-2025 | Serostim |
| Shionogi INC | $516.24 | 2020-2024 | Fetroja |
| La Jolla Pharmaceutical Company | $482.01 | 2020-2024 | Xerava, Xacduro |
| Astellas Pharma US INC | $330.22 | 2019-2022 | |
| Allergan, INC. | $269.53 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $247.01 | 2020-2022 | |
| Melinta Therapeutics, LLC | $246.69 | 2019-2023 | Rezzayo, Orbactiv, Kimyrsa |
| Cipla USA INC. | $221.40 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $200.82 | 2019-2023 | Pico 7, Renasys Go V2 Home, Acticoat 4" X 4" |
| Janssen Products, Lp | $198.95 | 2020-2021 | |
| Kci USA, INC. | $160.34 | 2019-2023 | 3m Cavilon, V.A.C. Dermatac, V.A.C. Veraflo |
| Tetraphase Pharmaceuticals, INC. | $133.78 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $117.23 | 2019 | |
| Kerecis Limited | $113.29 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Ibsa Pharma INC. | $88.48 | 2020 | |
| Janssen Pharmaceuticals, INC | $62.03 | 2021 | |
| Phathom Pharmaceuticals, INC. | $53.58 | 2024 | Voquezna |
| Mayne Pharma Commercial LLC | $46.84 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $36.26 | 2022-2023 | Rebyota |
| Bioventus LLC | $29.40 | 2022 | |
| Teleflex LLC | $25.63 | 2024 | Quikclot |
| Reddress USA, INC. | $25.55 | 2024 | |
| Hydrofera LLC | $23.03 | 2023 | Cutimed Sorbact |
| Boston Scientific Corporation | $20.65 | 2025 | Watchman Flx |
| Cashflow Solutions, LLC | $18.16 | 2022 | |
| Nabriva Therapeutics, Plc | $15.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carson Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.